bluuebunny/crossref_metadata_2025_split huggingface dataset:
National initiatives to promote quality of care and patient safety: achievements to date and challenges ahead
Authors: Dreiher Dalia , Blagorazumnaya Olga , Balicer Ran , Dreiher Jacob 
Published: November 2020

Abstract
Background
The quality of healthcare in Israel is considered “high”, and this achievement is due to the structure and organization of the healthcare system. The goal of the present review is to describe the major achievements and challenges of quality improvement in the Israeli healthcare system.

Body
In recent years, the Ministry of Health has made major strides in increasing the public’s access to comparative data on quality, finances and patient satisfaction. Several mechanisms at multiple levels help promote quality improvement and patient safety. These include legislation, financial incentives, and national programs for quality indicators, patient experience, patient safety, prevention and control of infection and accreditation. Over the years, improvements in quality indicators, infection prevention and patient satisfaction can be demonstrated, but other fields show little change, if at all. Challenges and barriers include reluctance by unions, inconsistent and unreliable flow of information, the fear of overpressure by management and the loss of autonomy by physicians, and doubts regarding “gaming” of data. Accreditation has its own challenges, such as the need to adjust it to local characteristics of the healthcare system, its high cost, and the limited evidence of its impact on quality. Lack of interest by leaders, lack of resources, burnout and compassion fatigue, are listed as challenges for improving patient experience.

Conclusion
Substantial efforts are being made in Israel to improve quality of care, based on the use of good data to understand what is working and what needs particular attention. Government and health care providers have the tools to continue to improve. However, several mechanisms for improving the quality of care, such as minimizing healthcare disparities, training for quality, and widespread implementation of the “choosing wisely” initiative, should be implemented more intensively and effectively.
DOANet: a deep dilated convolutional neural network approach for search and rescue with drone-embedded sound source localization
Authors: Qayyum Alif Bin Abdul , Hassan K. M. Naimul , Anika Adrita , Shadiq Md. Farhan , Rahman Md Mushfiqur , Islam Md. Tariqul , Imran Sheikh Asif , Hossain Shahruk , Haque Mohammad Ariful 
Published: November 2020

Abstract
Drone-embedded sound source localization (SSL) has interesting application perspective in challenging search and rescue scenarios due to bad lighting conditions or occlusions. However, the problem gets complicated by severe drone ego-noise that may result in negative signal-to-noise ratios in the recorded microphone signals. In this paper, we present our work on drone-embedded SSL using recordings from an 8-channel cube-shaped microphone array embedded in an unmanned aerial vehicle (UAV). We use angular spectrum-based TDOA (time difference of arrival) estimation methods such as generalized cross-correlation phase-transform (GCC-PHAT), minimum-variance-distortion-less-response (MVDR) as baseline, which are state-of-the-art techniques for SSL. Though we improve the baseline method by reducing ego-noise using speed correlated harmonics cancellation (SCHC) technique, our main focus is to utilize deep learning techniques to solve this challenging problem. Here, we propose an end-to-end deep learning model, called DOANet, for SSL. DOANet is based on a one-dimensional dilated convolutional neural network that computes the azimuth and elevation angles of the target sound source from the raw audio signal. The advantage of using DOANet is that it does not require any hand-crafted audio features or ego-noise reduction for DOA estimation. We then evaluate the SSL performance using the proposed and baseline methods and find that the DOANet shows promising results compared to both the angular spectrum methods with and without SCHC. To evaluate the different methods, we also introduce a well-known parameter—area under the curve (AUC) of cumulative histogram plots of angular deviations—as a performance indicator which, to our knowledge, has not been used as a performance indicator for this sort of problem before.
Mean-field anticipated BSDEs driven by time-changed Lévy noises
Authors: Liu Youxin , Dai Yang 
Published: November 2020

AbstractThe objective of this work is to show a new kind of mean-field anticipated backward stochastic differential equation (in short MF-ABSDE) driven by time-changed Lévy noises. We give two methods to prove the existence and uniqueness of the solution of those equations by the fixed point theorem and the Picard iterative sequence. Finally, we obtain a comparison theorem for the solutions.
Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas
Authors: Lazow Margot A. , Hoffman Lindsey , Schafer Austin , Osorio Diana S. , Boué Daniel R. , Rush Sarah , Wright Erin , Lane Adam , DeWire-Schottmiller Mariko D. , Smolarek Teresa , Sipple Jared , Taggert Heather , Reuss Jaime , Salloum Ralph , Hummel Trent R. , de Blank Peter , Pillay-Smiley Natasha , Sutton Mary E. , Asher Anthony , Stevenson Charles B. , Drissi Rachid , Finlay Jonathan L. , Fouladi Maryam , Fuller Christine 
Published: November 2020

Abstract
Recent discoveries have provided valuable insight into the genomic landscape of pediatric low-grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted treatment. However, little is known about their temporal and therapy-related genomic heterogeneity. An adequate understanding of the evolution of pediatric LGGs’ genomic profiles over time is critically important in guiding decisions about targeted therapeutics and diagnostic biopsy at recurrence. Fluorescence in situ hybridization, mutation-specific immunohistochemistry, and/or targeted sequencing were performed on paired tumor samples from primary diagnostic and subsequent surgeries. Ninety-four tumor samples from 45 patients (41 with two specimens, four with three specimens) from three institutions underwent testing. Conservation of BRAF fusion, BRAFV600E mutation, and FGFR1 rearrangement status was observed in 100%, 98%, and 96% of paired specimens, respectively. No loss or gain of IDH1 mutations or NTRK2, MYB, or MYBL1 rearrangements were detected over time. Histologic diagnosis remained the same in all tumors, with no acquired H3K27M mutations or malignant transformation. Changes in CDKN2A deletion status at recurrence occurred in 11 patients (42%), with acquisition of hemizygous CDKN2A deletion in seven and loss in four. Shorter time to progression and shorter time to subsequent surgery were observed among patients with acquired CDKN2A deletions compared to patients without acquisition of this alteration [median time to progression: 5.5 versus 16.0 months (p = 0.048); median time to next surgery: 17.0 months versus 29.0 months (p = 0.031)]. Most targetable genetic aberrations in pediatric LGGs, including BRAF alterations, are conserved at recurrence and following chemotherapy or irradiation. However, changes in CDKN2A deletion status over time were demonstrated. Acquisition of CDKN2A deletion may define a higher risk subgroup of pediatric LGGs with a poorer prognosis. Given the potential for targeted therapies for tumors harboring CDKN2A deletions, biopsy at recurrence may be indicated in certain patients, especially those with rapid progression.
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Authors: Sardesai Sagar , Sukumar Jasmine , Kassem Mahmoud , Palettas Marilly , Stephens Julie , Morgan Evan , Addison Daniel , Baliga Ragavendra , Stover Daniel G. , VanDeusen Jeffrey , Williams Nicole , Cherian Mathew , Lustberg Maryam , Wesolowski Robert , Ramaswamy Bhuvaneswari 
Published: November 2020

Abstract

Background
Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing treatment interruption or discontinuation.

Methods
The primary objective of the study was to evaluate disease-free survival (DFS) in non-metastatic, HER2-positive, female BC patients who experienced treatment interruption or early discontinuation of trastuzumab therapy. Clinical and histopathological data were collected on 400 patients at The Ohio State University, an NCI-designated comprehensive cancer center between January 2005 and December 2015. Treatment interruption was defined as any delay of ≥2 weeks during trastuzumab therapy, including permanent cessation prior to completing planned therapy. TIC was defined as LVEF < 50% or > 15 points decline from baseline as evaluated by 2D echocardiogram after initiation of (neo) adjuvant therapy. DFS was defined as the time from diagnosis to first recurrence (loco-regional or distant recurrence) including second primary BC or death. Overall survival (OS) was defined as the time from diagnosis to death or last known follow up. OS/DFS estimates were generated using Kaplan-Meier methods and compared using Log-rank tests. Cox proportional hazard models were used to calculate adjusted hazard ratios (aHR) for OS/DFS.

Results
A total of 369 patients received trastuzumab therapy; 106 (29%) patients experienced treatment interruption at least once and 42 (11%) permanently discontinued trastuzumab prior to completing planned therapy. TIC was the most common reason for interruption (66 patients, 62%). The median duration of trastuzumab in patients with treatment interruption was 11.3 months (range: 0.5–16.9) with 24 (23%) patients receiving ≤6 months of therapy. This duration includes the time delay related to treatment interruption. Patients with any treatment interruption had worse DFS (aHR: 4.4, p = 0.001) and OS (aHR: 4.8, p < 0.001) after adjusting for age, stage, grade, ER, node status and TIC.

Conclusions
Treatment interruption or early discontinuation of trastuzumab therapy in early HER2-positive BC, most often from TIC, is an independent prognostic marker for worse DFS and OS in operable HER2-positive BC. Future prospective studies should consider targeting at-risk populations and optimizing cardiac function to avoid interruption in trastuzumab therapy.
Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease
Authors: Paria Kishalay , Paul Debarati , Chowdhury Trinath , Pyne Smritikana , Chakraborty Ranadhir , Mandal Santi M. 
Published: November 2020

AbstractSince the birth of Christ, in these 2019 years, the man on earth has never experienced a survival challenge from any acellular protist compared to SARS-CoV-2. No specific drugs yet been approved. The host immunity is the only alternative to prevent and or reduce the infection and mortality rate as well. Here, a novel mechanism of melanin mediated host immunity is proposed having potent biotechnological prospects in health care management of COVID-19. Vitamin D is known to enhance the rate of melanin synthesis; and this may concurrently regulate the expression of furin expression. In silico analyses have revealed that the intermediates of melanin are capable of binding strongly with the active site of furin protease. On the other hand, furin expression is negatively regulated via 1-α-hydroxylase (CYP27B1), that belongs to vitamin-D pathway and controls cellular calcium levels. Here, we have envisaged the availability of biological melanin and elucidated the bio-medical potential. Thus, we propose a possible synergistic application of melanin and the enzyme CYP27B1 (regulates vitamin D biosynthesis) as a novel strategy to prevent viral entry through the inactivation of furin protease and aid in boosting our immunity at the cellular and humoral levels.
Denouements of machine learning and multimodal diagnostic classification of Alzheimer’s disease
Authors: Naik Binny , Mehta Ashir , Shah Manan 
Published: November 2020

Abstract
Alzheimer’s disease (AD) is the most common type of dementia. The exact cause and treatment of the disease are still unknown. Different neuroimaging modalities, such as magnetic resonance imaging (MRI), positron emission tomography, and single-photon emission computed tomography, have played a significant role in the study of AD. However, the effective diagnosis of AD, as well as mild cognitive impairment (MCI), has recently drawn large attention. Various technological advancements, such as robots, global positioning system technology, sensors, and machine learning (ML) algorithms, have helped improve the diagnostic process of AD. This study aimed to determine the influence of implementing different ML classifiers in MRI and analyze the use of support vector machines with various multimodal scans for classifying patients with AD/MCI and healthy controls. Conclusions have been drawn in terms of employing different classifier techniques and presenting the optimal multimodal paradigm for the classification of AD.
Interleukin-18 polymorphism as a diagnostic tumor marker for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis
Authors: Eldesoky Ayman Abdelghaffar , Ahmed Nancy Abdel Fattah , Zaghloul Hosam Eldeen , Aziz Amr Ahmed Abdel 
Published: November 2020

Abstract

Background
Egypt has the highest hepatitis C virus prevalence worldwide where about 24% of the people are estimated to carry HCV and more than 50% of blood donors have anti-HCV in some towns. The burden of hepatocellular carcinoma has been increasing in Egypt with a doubling in the incidence rate in the past 10 years. Thus, the aim of the present study was to analyze the interleukin-18 single nucleotide polymorphisms (SNPs) as a diagnostic tumor marker for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Results
This study included 33 hepatocellular carcinoma (HCC) complicating HCV-related cirrhosis patients, 37 cirrhotic patients without HCC (cirrhosis group), and 20 healthy individuals who were included as a control for 9 months of follow-up. SNPs of the IL-18 gene were genotyped by polymerase chain reaction. There was a statistically significant difference in the GG genotype in the HCC group in comparison with the control group (P = 0.04). There was a statistically significant difference in the G allele in the cirrhosis and HCC groups in comparison with the control group (p1 < 0.001 and p2 = 0.03, respectively). Patients with GC genotype have a risk for developing HCC by 6.33-folds more than those with GG genotype while patients with GC genotype have a risk for developing cirrhosis by 5.43-folds more than those with GG genotype, and cirrhotic patients with CC and GC genotype had a risk for developing HCC by 1.17-folds more than those with GG genotype.

Conclusion
Our findings revealed that the analysis of IL-18 single nucleotide gene polymorphism could be a valuable marker for the prediction of progress towards cirrhosis in chronic HCV patients and also to subsequent development of HCC in HCV cirrhotic patients proved by the results of both GG genotype and its G allele; also, cirrhotic patients with CC and GC genotype have a risk for developing HCC by 1.17-folds more than those with GG genotype.
Multiple Endocrine Deficiencies are Common in Hypoparathyroidism–Retardation–Dysmorphism Syndrome
Authors: David Odeya , Barash Galia , Agur Rotem , Loewenthal Neta , Carmon Lior , Shaki David , Walker Dganit , Novoa Rosa , Haim Alon , Hershkovitz Eli 
Published: November 2020

Abstract

Context
The rare hypoparathyroidism—retardation—dysmorphism (HRD) syndrome (OMIM #241410) is caused by the mutated tubulin chaperone E (TBCE) gene. This gene encodes a critical protein in the microtubule assembly pathway.

Objective
To evaluate the endocrine profile of patients with HRD.

Methods
The study used a retrospective analysis of a large cohort of patients in a single university medical center. Sixty-three patients were diagnosed with HRD during 1990 to 2019; 58 of them had an endocrine evaluation.

Main outcome measures
We investigated somatic growth parameters, the prevalence of hypoglycemia, growth hormone deficiency, hypothyroidism, hypogonadism, and cortisol deficiency.

Results
All patients were born small for gestational age, and severe growth retardation was found in all patients with mean height standard deviation score (SDS) of –8.8 (range: –5.1 to –15.1) and weight SDS –18 (range: –5.1 to –61.2). Serum insulin-like growth factor-1 concentrations were very low among the 21 studied patients: –2.32 SDS (range: –0.6 to –2.7). Four out of 14 (28%) investigated patients had growth hormone deficiency, and 55% of patients were hospitalized due to symptomatic hypoglycemia. Adrenal glucocorticoid insufficiency was diagnosed in 22% of those tested. Hypothyroidism was found in 36% of patients. Both hypogonadotrophic and hypergonadotrophic hypogonadism were observed. The main magnetic resonance imaging findings were small anterior pituitary gland, small hippocampus, brain atrophy, thin corpus callosum, Chiari type I malformation, and septo-optic dysplasia.

Conclusion
Multiple endocrine abnormalities are common in patients with HRD syndrome. Periodic screening of thyroid and adrenal functions is recommended.
Art, Dispossession, and Imaginations of Historical Justice
Authors: Karaca Banu 
Published: November 2020

AbstractDrawing on the works of artists Maria Eichhorn (Berlin) and Dilek Winchester (Istanbul), this article focuses on artistic responses to the twin processes of violence and dispossession in Germany and the late Ottoman Empire and republican Turkey, respectively. Their artistic practices respond to what is irrecoverable in loss, in contrast to dominant discussions on material restitution as a process that always projects a reversibility of past injuries and that remains limited to the logic of possession. The article argues that these practices pose an aesthetic challenge to the conceptual frameworks within which both dispossession and restitution are usually understood. They produce forms of aesthetic redistribution that open paths to alternate ways of envisioning historical justice in transformative rather than recuperative terms.
FGF2 and IL-1β – explorers of unconventional secretory pathways at a glance
Authors: Pallotta Maria Teresa , Nickel Walter 
Published: November 2020

ABSTRACT
Fibroblast growth factor 2 (FGF2) and interleukin 1β (IL-1β) were among the earliest examples of a subclass of proteins with extracellular functions that were found to lack N-terminal secretory signal peptides and were shown to be secreted in an ER- and Golgi-independent manner. Many years later, a number of alternative secretory pathways have been discovered, processes collectively termed unconventional protein secretion (UPS). In the course of these studies, unconventional secretion of FGF2 and IL-1β were found to be based upon distinct pathways, mechanisms and molecular machineries. Following a concise introduction into various pathways mediating unconventional secretion and transcellular spreading of proteins, this Cell Science at a Glance poster article aims at a focused analysis of recent key discoveries providing unprecedented detail about the molecular mechanisms and machineries driving FGF2 and IL-1β secretion. These findings are also highly relevant for other unconventionally secreted cargoes that, like FGF2 and IL1β, exert fundamental biological functions in biomedically relevant processes, such as tumor-induced angiogenesis and inflammation.
Status of the WHO recommended timing and frequency of antenatal care visits in Northern Bangladesh
Authors: Sarker Bidhan Krishna , Rahman Musfikur , Rahman Tanjina , Rahman Tawhidur , Khalil Jubaida Jahan , Hasan Mehedi , Rahman Fariya , Ahmed Anisuddin , Mitra Dipak Kumar , Mridha Malay Kanti , Rahman Anisur 
Published: November 2020

Objective
There is dearth of information on the timeliness of antenatal care (ANC) uptake. This study aimed to determine the timely ANC uptake by a medically trained provider (MTP) as per the World Health Organization (WHO) recommendations and the country guideline.

Methods
Cross-sectional survey was done with 2,731 women having livebirth outcome in last one year in Dinajpur, Nilphamari and Rajshahi districts, Bangladesh from August-November,2016.

Results
About 82%(2,232) women received at least one ANC from a MTP. Overall, 78%(2,142) women received 4 or more ANCs by any provider and 43%(1168) from a MTP. Only 14%(378) women received their first ANC at the 1st trimester by a MTP. As per 4 schedule visits by the WHO FANC model and the country guideline 8%(203) and 20%(543) women respectively received the first 2 timely ANC by a MTP; where only 1%(32) and 3%(72) received the first 3 visits timely and 0.6%(17) and 1%(29) received all the four timely visits. Factors significantly associated with the first two timely visits are: 10 or above years of schooling of women [adj. OR 2.13 (CI: 1.05, 4.30)] and their husbands [adj. OR 2.40 (CI: 1.31, 4.38)], women’s employment [adj. OR 2.32 (CI: 1.43, 3.76)], urban residential status [adj. OR 3.49 (CI: 2.46, 4.95)] and exposure to mass media [adj. OR 1.58 (CI: 1.07, 2.34)] at 95% confidence interval. According to the 2016 WHO ANC model, only 1.5%(40) women could comply with the first two ANC contacts timely by a MTP and no one could comply with all the timely 8 contacts.

Conclusion
Despite high coverage of ANC utilization, timely ANC visit is low as per both the WHO recommendations and the country guideline. For better understanding, further studies on the timeliness of ANC coverage are required to design feasible intervention for improving maternal and child health.
Commonly used clinical chemistry tests as mortality predictors: Results from two large cohort studies
Authors: Lind Lars , Zanetti Daniela , Högman Marieann , Sundman Lars , Ingelsson Erik 
Published: November 2020

Background
The normal ranges for clinical chemistry tests are usually defined by cut-offs given by the distribution in healthy individuals. This approach does however not indicate if individuals outside the normal range are more prone to disease.

Methods
We studied the associations and risk prediction of 11 plasma and serum biomarkers with all-cause mortality in two population-based cohorts: a Swedish cohort (X69) initiated in 1969, and the UK Biobank (UKB) initiated in 2006–2010, with up to 48- and 9-years follow-up, respectively.

Results
In X69 and in UKB, 18,529 and 425,264 individuals were investigated, respectively. During the follow-up time, 14,475 deaths occurred in X69 and 17,116 in UKB. All evaluated tests were associated with mortality in X69 (P<0.0001, except bilirubin P<0.005). For calcium, blood urea nitrogen, bilirubin, hematocrit, uric acid, and iron, U-shaped associations were seen (P<0.0001). For leukocyte count, gamma-glutamyl transferase, alkaline phosphatases and lactate dehydrogenase, linear positive associations were seen, while for albumin the association was negative. Similar associations were seen in UKB. Addition of all biomarkers to a model with classical risk factors improved mortality prediction (delta C-statistics: +0.009 in X69 and +0.023 in UKB, P<0.00001 in both cohorts).

Conclusions
Commonly used clinical chemistry tests were associated with all-cause mortality both in the medium- and long-term perspective, and improved mortality prediction beyond classical risk factors. Since both linear and U-shaped relationships were found, we propose to define the normal range of a clinical chemistry test based on its association with mortality, rather than from the distribution.